FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
You may also be interested in...
Despite few public announcements and industry concerns, FDA's Office of Pharmaceutical Quality director says program is not dead.
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.